Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
Source: AJMC, May 2024
A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Patients with advanced melanoma can still experience adverse effects (AEs) from immune checkpoint modulator (ICM) therapy a year after their treatment initiation, according to a recent study published in Supportive Care in Cancer. These findings stress the need for ongoing adverse effect management and screening in long-term survivors of advanced melanoma.
In the US, advanced melanoma affects an estimated 66,000 people.1 ICM therapy has altered the trajectory of this cancer, drastically improved survival rates, and become the standard of care (SOC) for immunotherapy in this area. Despite their beneficial impacts on patient outcomes, immune-related AEs (irAEs) occur at rates over 90% in patients who receive this treatment.